Evoke Pharma – Treatment for Diabetic Gastroparesis

Matthew D’Onofrio, co-founder, President and COO of Evoke Pharma, a specialty pharmaceutical company focused on the treatment of gastrointestinal diseases discusses GIMOTI ®, the first and only FDA-approved nasal formulation of metoclopramide that is commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis (DGP).

Matthew J. D’Onofrio is one of Evoke Pharma’s co-founders and currently serves as the Company’s President and COO. Mr. D’Onofrio has over 25 years of experience in both large and small pharmaceutical firms. Prior to founding Evoke, Mr. D’Onofrio was Vice President, Business Development for Victory Pharma, a biopharmaceutical company focused on acquiring, developing, and marketing products to treat pain and related conditions. Mr. D’Onofrio was previously Director and Head of West Coast Business Development at Vertex Pharmaceuticals, a biotechnology company, directing partnership efforts associated with the La Jolla research facility as well as other corporate assets. Mr. D’Onofrio also held various commercial roles of increasing responsibility over a decade at Eli Lilly & Company, including significant experience in worldwide corporate business development. Mr. D’Onofrio has developed and executed license and investment relationships across a wide collection of disease states and technologies. Mr. D’Onofrio earned a B.S. in Chemistry from San Diego State University and an M.B.A. (Finance) from the Marshall School of Business, University of Southern California.

Liked it? Take a second to support healthprofessionalradio on Patreon!
Become a patron at Patreon!


Leave a Reply

You must be logged in to post a comment.